Literature DB >> 17717313

Clinical diagnosis of lacunar stroke in the first 6 hours after symptom onset: analysis of data from the glycine antagonist in neuroprotection (GAIN) Americas trial.

Stephen J Phillips1, Dingwei Dai, Arnold Mitnitski, Gordon J Gubitz, Karen C Johnston, Walter J Koroshetz, Karen L Furie, Sandra Black, Darell E Heiselman.   

Abstract

BACKGROUND AND
PURPOSE: Although the pathophysiological heterogeneity of stroke may be highly relevant to the development of acute-phase therapies, discriminating between ischemic stroke subtypes soon after onset remains a challenge. We conducted a study of the accuracy of a clinical diagnosis of lacunar stroke in the first 6 hours after symptom onset.
METHODS: We analyzed data from 1367 patients in the Glycine Antagonist In Neuroprotection (GAIN) Americas trial. The Trial of ORG10172 in Acute Stroke Treatment (TOAST) category "small vessel (lacunar)" disease at day 7 or at hospital discharge was used as the reference standard to determine the accuracy of a diagnosis of a lacunar stroke made within 6 hours of symptom onset using the Oxfordshire Community Stroke Project (OCSP) classification "LACS." Outcome was analyzed by comparing the proportions of patients classified as "LACS" at baseline or "small vessel (lacunar)" at 7 days who were dead or dependent at 3 months.
RESULTS: The positive predictive value of an OCSP diagnosis of a lacunar stroke was 76% (95% CI: 69% to 81%; sensitivity 64% [95% CI: 58% to 70%]; specificity 96% [95% CI: 95% to 97%]; negative predictive value 93% [95% CI: 92% to 94%]; accuracy 91% [95% CI: 89% to 92%]). The 3-month outcomes of patients classified as either OCSP "LACS" within 6 hours of onset or TOAST "small vessel (lacunar)" at 7 days were not significantly different.
CONCLUSIONS: An OCSP LACS diagnosis made within 6 hours of stroke onset is reasonably predictive of a final diagnosis of "small vessel (lacunar)" disease made using TOAST criteria and has a similar relationship to outcome at 3 months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717313      PMCID: PMC2747476          DOI: 10.1161/STROKEAHA.107.487744

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  37 in total

1.  The role of the clinical examination in the subclassification of stroke.

Authors:  J M Bamford
Journal:  Cerebrovasc Dis       Date:  2000       Impact factor: 2.762

2.  Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.

Authors:  Steven Warach; David Kaufman; David Chiu; Thomas Devlin; Marie Luby; Ajaz Rashid; Linda Clayton; Markku Kaste; Kennedy R Lees; Ralph Sacco; Marc Fisher
Journal:  Cerebrovasc Dis       Date:  2005-12-09       Impact factor: 2.762

3.  Trials: the next 50 years. Large scale randomised evidence of moderate benefits.

Authors:  R Peto; C Baigent
Journal:  BMJ       Date:  1998-10-31

4.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

5.  The arterial lesions underlying lacunes.

Authors:  C M Fisher
Journal:  Acta Neuropathol       Date:  1968-12-18       Impact factor: 17.088

6.  Correlation between symptomatic, radiological and etiological diagnosis in acute ischemic stroke.

Authors:  H Tei; S Uchiyama; K Koshimizu; M Kobayashi; K Ohara
Journal:  Acta Neurol Scand       Date:  1999-03       Impact factor: 3.209

7.  Normal diffusion-weighted MRI during stroke-like deficits.

Authors:  H Ay; F S Buonanno; G Rordorf; P W Schaefer; L H Schwamm; O Wu; R G Gonzalez; K Yamada; G A Sorensen; W J Koroshetz
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

8.  How well does the Oxfordshire community stroke project classification predict the site and size of the infarct on brain imaging?

Authors:  G E Mead; S C Lewis; J M Wardlaw; M S Dennis; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

Review 10.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

View more
  4 in total

1.  Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.

Authors:  Johan Undén; Karin Strandberg; Jan Malm; Eric Campbell; Lars Rosengren; Johan Stenflo; Bo Norrving; Bertil Romner; Arne Lindgren; Gunnar Andsberg
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

2.  Baseline NIH stroke scale responses estimate the probability of each particular stroke subtype.

Authors:  E C Leira; H P Adams; G E Rosenthal; J C Torner
Journal:  Cerebrovasc Dis       Date:  2008-10-23       Impact factor: 2.762

3.  Risk Factors for Silent Lacunar Infarction in Patients with Transient Ischemic Attack.

Authors:  Ying Li; Nan Liu; Yonghua Huang; Wei Wei; Fei Chen; Weiwei Zhang
Journal:  Med Sci Monit       Date:  2016-02-11

4.  Improving Clinical Detection of Acute Lacunar Stroke: Analysis From the IST-3.

Authors:  Francesco Arba; Grant Mair; Stephen Phillips; Peter Sandercock; Joanna M Wardlaw
Journal:  Stroke       Date:  2020-04-09       Impact factor: 7.914

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.